GIP receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Iran hit Stryker, a US-based medical supply company with a cyberattack. On 12 March, UNICEF reported that 300 children had been killed, thousands injured, hundreds of thousands displaced, and millions unable to attend schools due to the war. Iranian deputy intelligence minister Akbar Ghaffari was killed in an airstrike. An Iranian attack set two tankers on fire off the Iraqi coast, killing one person. The historical Safavid-era building of Rashk-e Jenan, was destroyed by US-Israeli strikes. Other buildings damaged included the Chehel Sotoun pavilion, Rakib Khaneh Mansion, Timurid Hall, Ashraf Hall and the Ali Qapu palace. Many affected buildings and monuments were legally protected by the Blue Shield International, which called damaging them a war crime. French soldiers were injured in a drone strike at a base in Iraqi Kurdistan. French president Emmanuel Macron announced on 13 March that a soldier was killed in the attack. On 13 March, to alleviate the economic costs of the war, the US temporarily lifted restrictions on the sale of Russian oil. Iran announced a coordinated offensive by its navy, army, and Hezbollah against Israel and US bases. Israel reported that 58 people have been hospitalized due to injuries following a missile strike. Kuwait authorities stated that defense equipment and the country's main airport were attacked, and power lines gone out of service. Missiles entered Turkish air space and were intercepted, with explosions heard near Adana. Israel struck IRGC checkpoints after receiving tip-offs by informants on the ground.
== Further reading == Love, Spencie (1996), One Blood: The Death and Resurrection of Charles R. Drew, Chapel Hill: University of North Carolina Press. Organ, Claude H. (ed.) (1987), A Century of Black Surgeons: The USA Experience, Vol. 1, Transcript Press, Asa G. Yancer Sr., "The Life Of Charles R. Drew, MD". Schraff, Anne E. (2003), Dr. Charles Drew: Blood Bank Innovator, Enslow. Wynes, Charles E. (1988), Charles Richard Drew: The Man and the Myth, University of Illinois Press.
Of increasing concern since the isolation of natural radium by Marie and Pierre Curie in 1898—and the subsequent advent of nuclear physics and nuclear technologies—are radiological poisons. These are associated with ionizing radiation, a mode of toxicity quite distinct from chemically active poisons. In mammals, chemical poisons are often passed from mother to offspring through the placenta during gestation, or through breast milk during nursing. In contrast, radiological damage can be passed from mother or father to offspring through genetic mutation, which—if not fatal in miscarriage or childhood, or a direct cause of infertility—can then be passed along again to a subsequent generation. Atmospheric radon is a natural radiological poison of increasing impact since humans moved from hunter-gatherer lifestyles and cave dwelling to increasingly enclosed structures able to contain radon in dangerous concentrations. The 2006 poisoning of Alexander Litvinenko was a notable use of radiological assassination, presumably meant to evade the normal investigation of chemical poisons. Poisons widely dispersed into the environment are known as pollution. These are often of human origin, but pollution can also include unwanted biological processes such as toxic red tide, or acute changes to the natural chemical environment attributed to invasive species, which are toxic or detrimental to the prior ecology (especially if the prior ecology was associated with human economic value or an established industry such as shellfish harvesting).
Sources: en.wikipedia.org
Like many other medical conditions, obesity is the result of an interplay between genetic and environmental factors. Polymorphisms in various genes controlling appetite and metabolism predispose to obesity when sufficient food energy is present. Advances in genome-wide association studies (GWAS) have since identified substantially more genomic loci linked to obesity susceptibility than were known in 2006, though the relative contribution of each remains an active area of research. People with two copies of the FTO gene (fat mass and obesity associated gene) have been found on average to weigh 3–4 kg more and have a 1.67-fold greater risk of obesity compared with those without the risk allele. The differences in BMI between people that are due to genetics varies depending on the population examined from 6% to 85%. Obesity is a major feature in several syndromes, such as Prader–Willi syndrome, Bardet–Biedl syndrome, Cohen syndrome, and MOMO syndrome. (The term "non-syndromic obesity" is sometimes used to exclude these conditions.) In people with early-onset severe obesity (defined by an onset before 10 years of age and body mass index over three standard deviations above normal), 7% harbor a single point DNA mutation. Studies that have focused on inheritance patterns rather than on specific genes have found that 80% of the offspring of two obese parents were also obese, in contrast to less than 10% of the offspring of two parents who were of normal weight. Different people exposed to the same environment have different risks of obesity due to their underlying genetics.
In Berezovka, a memorial steel was erected in 1972. In Bychivka Station: A memorial plaque was dedicated in 1965. In Dubrova: a Monument was erected in 1979 commemorating the 1943 raid on the local German Garrison.
=== Rubber transferases === Currently the only available commercial source of natural rubber is the Hevea plant (Hevea brasiliensis). Natural rubber is superior to synthetic rubber in a number of commercial uses. Efforts are being made to produce transgenic plants capable of synthesizing natural rubber, including tobacco and sunflower. These efforts are focused on sequencing the subunits of the rubber transferase enzyme complex in order to transfect these genes into other plants.
Sources: en.wikipedia.org
== Toxicity and safety == Glycerol has very low toxicity when ingested; its LD50 oral dose for rats is 12600 mg/kg and 8700 mg/kg for mice. It does not appear to cause toxicity when inhaled, although changes in cell maturity occurred in small sections of lung in animals under the highest dose measured. A sub-chronic 90-day nose-only inhalation study in Sprague Dawley rats exposed to 0.03, 0.16 and 0.66 mg of glycerin per liter of air for 6-hour continuous sessions revealed no treatment-related toxicity other than minimal metaplasia of the epithelium lining at the base of the epiglottis in rats exposed to 0.66 mg/L glycerin.
=== Claims of innocence === Norris appealed against his conviction in 2009. Originally, Norris planned to appeal on the grounds that the trial judge had shown a "lack of balance", but then scrapped these plans and sacked his legal team. He subsequently appealed on the grounds that the judge had "misdirected" the jury in his final summary but he lost this appeal, with judge Lord Justice Aikens ruling the convictions were "safe" and saying that the case against Norris was "very strong indeed". The appeal court rejected both grounds of the appeal, saying that the judge's directions "cannot validly be criticised" and that there was no misdirection to the jury. The appeal court instead said that the judge's summary in the original case was an exemplary "tour de force". The judges also refused to believe that the deaths were "coincidental". Norris's defence team had argued that the deaths could have been the result of 'naturally' raised insulin levels caused by severe spontaneous hypoglycaemia, but the judges rejected this possibility. On 4 October 2011, the BBC reported that retired Professor Vincent Marks – a leading expert on insulin poisoning – was concerned about Norris's conviction. He had been asked by the Norris family to find evidence in the case. He claimed the jury at Norris's trial was wrongly led to believe by experts that a cluster of hypoglycaemic episodes, among people who were not diabetic, was sinister. After carrying out his own studies, he said: "Looking at all the evidence, all I can say is I think Colin Norris's conviction is unsafe".
Epidermal growth factor (EGF) is a protein that stimulates cell growth and differentiation by binding to its receptor, EGFR. Human EGF is 6-kDa and has 53 amino acid residues and three intramolecular disulfide bonds. EGF was originally described as a secreted peptide found in the submaxillary glands of mice and in human urine. EGF has since been found in many human tissues, including platelets, submandibular gland (submaxillary gland), and parotid gland. Initially, human EGF was known as urogastrone.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.